Additional borrowing capacity

  
NOTE 14. FINANCING The components of the Company’s debt as of December 31 were as follows (amounts in millions):

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Outstanding Amount |  |  |
| Description and Aggregate Principal Amount |  | 2021 |  | 2020 |  |  |
| U.S. dollar-denominated commercial paper |  | $ | 1,440  |  |  | $ | —  |  |  |  |
| Euro-denominated commercial paper (€1.2 billion and €500 million, respectively) |  | 1,366  |  |  | 611  |  |  |  |
| Zero-coupon LYONs due 1/22/2021 |  | —  |  |  | 24  |  |  |  |
| 0.352% senior unsecured notes due 3/16/2021 (¥30.0 billion) (the “2021 Yen Notes”) |  | —  |  |  | 290  |  |  |  |
|  |  |  |  |  |  |  |
| Floating rate senior unsecured notes due 6/30/2022 (€250 million) (the “Floating Rate 2022 Euronotes”) |  | 284  |  |  | 305  |  |  |  |
| 2.05% senior unsecured notes due 11/15/2022 (the “2022 Biopharma Notes”) |  | 699  |  |  | 698  |  |  |  |
| 0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”) |  | 592  |  |  | 611  |  |  |  |
| 1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”) |  | 1,021  |  |  | 1,096  |  |  |  |
| 2.2% senior unsecured notes due 11/15/2024 (the “2024 Biopharma Notes”) |  | 698  |  |  | 697  |  |  |  |
| 2.5% senior unsecured notes due 7/08/2025 (€800 million) (the “2025 Euronotes”) |  | —  |  |  | 975  |  |  |  |
| 3.35% senior unsecured notes due 9/15/2025 (the “2025 U.S. Notes”) |  | 498  |  |  | 498  |  |  |  |
| 0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) |  | 1,416  |  |  | 1,520  |  |  |  |
| 2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) |  | 907  |  |  | 975  |  |  |  |
| 0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) |  | 267  |  |  | 297  |  |  |  |
| 1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) |  | 680  |  |  | 729  |  |  |  |
| 0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) |  | 1,413  |  |  | 1,518  |  |  |  |
| 1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) |  | 233  |  |  | 241  |  |  |  |
| 2.6% senior unsecured notes due 11/15/2029 (the “2029 Biopharma Notes”)  |  | 795  |  |  | 795  |  |  |  |
| 2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) |  | 910  |  |  | 978  |  |  |  |
| 0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) |  | 1,980  |  |  | 2,127  |  |  |  |
| 0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) |  | 461  |  |  | 514  |  |  |  |
| 1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) |  | 1,406  |  |  | 1,511  |  |  |  |
| 3.25% senior unsecured notes due 11/15/2039 (the “2039 Biopharma Notes”)  |  | 890  |  |  | 889  |  |  |  |
| 4.375% senior unsecured notes due 9/15/2045 (the “2045 U.S. Notes”) |  | 499  |  |  | 499  |  |  |  |
| 1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) |  | 844  |  |  | 907  |  |  |  |
| 3.4% senior unsecured notes due 11/15/2049 (the “2049 Biopharma Notes”) |  | 889  |  |  | 889  |  |  |  |
| 2.6% senior unsecured notes due 10/01/2050 (the “2050 U.S. Notes”) |  | 980  |  |  | 979  |  |  |  |
| 2.8% senior unsecured notes due 12/10/2051 (the “2051 U.S. Notes”) |  | 983  |  |  | —  |  |  |  |
| Other |  | 25  |  |  | 31  |  |  |  |
| Total debt |  | 22,176  |  |  | 21,204  |  |  |  |
| Less: currently payable |  | (8) |  |  | (11) |  |  |  |
| Long-term debt |  | $ | 22,168  |  |  | $ | 21,193  |  |  |  |

Debt discounts, premiums and debt issuance and other related costs totaled $130 million and $132 million as of December 31, 2021 and 2020, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above.Commercial Paper Programs and Credit FacilitiesIn 2019, the Company entered into a $5.0 billion unsecured revolving credit facility with a syndicate of banks that expires on August 27, 2024, subject to a one-year extension option at the request of the Company with the consent of the lenders (the “Five-Year Facility”). The Five-Year Facility also contains an expansion option permitting Danaher to request up to five increases of up to an aggregate additional $2.5 billion from lenders that elect to make such increase available, upon the satisfaction of certain conditions. At the same time, the Company entered into a $5.0 billion 364-day unsecured revolving 93
